Supplement to Nov-Dec 2015 Issue: Abstracts of Poster Presentations: CNS Summit 2015

Conclusions: Therapeutic and supra-therapeutic doses of flibanserin had no negative effect on measures of next-day simulated driving performance and cognitive testing.   Effect of as-needed use of intranasal PH94B on social and performance anxiety in individuals with social anxiety disorder Presenters: Liebowitz M, Hanover R, Draine A, Lemming R, Careri J, Monti L Affiliations: The Medical Research Network, LLC Background: There are no medications approved for use on an as-needed basis for feared social or performance situations for individuals with social anxiety disorder. Objective: In the present study, PH94B, a novel synthetic neurosteroidal molecule that is administered intranasally in microgram doses, was used as needed during everyday stressful social events. Methods: Twenty-two subjects were randomized (double-blind) to two weeks of treatment with intranasal PH94B or placebo. Following self-administration of medication prior to an anticipated fearful event, peak levels of anxiety were recorded using the Subjective Units of Distress Scale (SUDS). Subjects were crossed over to the opposite treatment for two weeks. Average peak SUDS during treatment with PH94B and placebo was compared. Results: Significant differences in favor of PH94B were found on the primary outcome measure. The mean SUDS peak score for all subjects receiving PH94B was 51.1 versus 58.4 for placebo (paired t: 3.09, p=0.006, effect size of 0.658). PH94B showed greater superiority over placebo when ...
Source: Innovations in Clinical Neuroscience - Category: Neuroscience Authors: Tags: Current Issue Drug Development Genetics Supplements Trial Methodology CNS Summit poster presentation abstracts Source Type: research